Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

HealthSource vs Onyx Weight Loss

HealthSource
Graded #97

Higher grade

vs+12.400000000000006
Onyx Weight Loss
Graded #358

Lower grade

The verdict

HealthSource takes it — 71.2/100 to 58.8/100.

HealthSource grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. HealthSource is a telehealth weight-management platform offering compounded semaglutide and tirzepatide (injectable and oral sublingual) dispensed through a US-based FDA 503A licensed partner pharmacy.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueHealthSource +23
66
43
Dose & formulationHealthSource +19
83
64
Clinical oversightHealthSource +5
80
75
Labs & monitoringOnyx Weight Loss +9
54
63
FulfillmentHealthSource +27
80
53
Contract termsEven
55
55
HealthSource · left barOnyx Weight Loss · right bar

The numbers

MetricHealthSourceOnyx Weight Loss
WeighScore71.2/10058.8/100
GradeCC
Scorecard rank#97#358
Semaglutide$199/mo (all doses, compounded)$228/mo (starting dose, compounded)
Tirzepatide$299/mo (all doses, compounded)$280/mo (starting dose, compounded)
CoverageAll 50 states8 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
HealthSource

Graded #97 · C

Strengths

  • Three GLP-1 options: compounded semaglutide injection, tirzepatide injection, and oral sublingual tirzepatide
  • 24/7 access to care team via HIPAA-compliant platform with unlimited physician messaging
  • Every program covers the cost of medication, supplies, and telehealth visits — no separate pharmacy fee
  • Subscription auto-refund if monthly reassessment is not completed
  • Available in all 50 US states including Alaska and Hawaii with 3–5 day shipping

Where it loses points

  • No physician names or clinical leadership disclosed on public pages
  • No LegitScript certification found
  • 503A partner pharmacy not named — less transparent than providers disclosing their 503B pharmacy
  • Labs not mentioned on any product page — baseline bloodwork protocol unknown
  • WooCommerce e-commerce storefront may feel more transactional than clinical
Onyx Weight Loss

Graded #358 · C

Strengths

  • Competitive entry pricing: semaglutide from $228/mo and tirzepatide from $280/mo with medication + supplies included
  • Nurse-practitioner-led care: founder Tasha Vangile FNP-C (20+ years) and Stephanie Robison APRN-CNP (27 years experience)
  • Low-cost $99/mo GLP-1 microdosing option for patients who prefer a gradual titration start
  • Strive Pharmacy partnership implies compounded 503A-quality supply chain from a known pharmacy
  • Multi-modal clinic: GLP-1 + peptides + HRT + nutrition coaching available under one provider team

Where it loses points

  • Only 8 states (NC, CO, ME, VT, VA, IA, NH, PA) — excludes the majority of the US
  • No LegitScript certification; credentialing evidence limited to local 2025 Best of Iredell award
  • Specific drug names (semaglutide/tirzepatide) never stated on website; compounded status inferred, not disclosed
  • Labs not included or mentioned; no baseline bloodwork protocol published
  • Pricing shown as 'Starting at' with no dose-escalation tier pricing disclosed publicly

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard